I-Mab
Sector: Manufacturing
Industry: Pharmaceutical Products
0.88
-0.01
(-1.12%)
Volume:
152,023
52 week range:
0.60 - 2.00
Market Cap:
7.172M
Company Description:
I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.